You are here

Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement

Last updated on March 11, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Kaohsiung, , 813 Taiwan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Prostate
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Taiwanese male subjects between 50 and 80 years of age who had: a primary diagnosis of
BPH, defined as having an enlarged prostate (confirmed by digital rectal examination
[DRE] and/or B-mode ultrasound); an IPSS score of ≥12; and a Qmax in the range of 5 to
15 mL/sec in a total voided volume of ≥150 mL, were eligible for the study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Previous prostate surgery, presence of a prostate stent or microwave thermotherapy
and/or balloon dilatation within the previous 6 months

- Concomitant therapy or previous therapy within 14 days with agents known to affect
bladder or urethral function.

NCT00648323
Pfizer
Completed
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Castration Resistant Prostate Cancer (CRPC), Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03460977
All Genders
18+
Years
Multiple Sites
Hormone Receptor Positive Advanced Breast Cancer, Metastatic Breast Cancer, Human Epidermal Receptor 2 Negative Advanced Breast Cancer, Castration Resistant Prostate Cancer
NCT03685591
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now